Valuation: Hemostemix Inc.

Market Cap 1.16Cr 82.25L 72.18L 68.17L 62.12L 79Cr 1.17Cr 8.16Cr 3.16Cr 40Cr 3.09Cr 3.02Cr 129.44Cr P/E 2024
-4.36x
P/E 2025 -3.12x
Enterprise Value 1.45Cr 1.02Cr 89.94L 84.94L 77.41L 98Cr 1.46Cr 10Cr 3.94Cr 50Cr 3.85Cr 3.76Cr 161.29Cr EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
83.37%
Yield 2024 *
-
Yield 2025 -
1 day-15.38%
1 week-21.43%
Current month-26.67%
1 month-21.43%
6 months-15.38%
Current year-38.89%
1 week 0.06
Extreme 0.055
0.07
1 month 0.06
Extreme 0.055
0.08
Current year 0.04
Extreme 0.04
0.11
1 year 0.04
Extreme 0.04
0.12
3 years 0.04
Extreme 0.035
0.42
5 years 0.04
Extreme 0.035
0.42
10 years 0
Extreme 0
5
Manager TitleAgeSince
Chief Executive Officer - 10/02/2020
Director of Finance/CFO - 05/03/2020
Chief Tech/Sci/R&D Officer - 14/10/2021
Director TitleAgeSince
Director/Board Member - 26/11/2019
Director/Board Member 67 09/02/2020
Director/Board Member - 08/04/2020
Date Insider Type Main position Quantity % Market Cap. Importance
30/07/26 Option

Chairman

5,25,000 0.2654%
22/07/26 Option

Director

3,85,000 0.1946%
22/07/26 Option

Founder

17,30,000 0.8746%
Change 5-day change 1-year change 3-year change Capi.($)
-15.38%-21.43%-42.11%-50.00% 82.25L
-3.30%+1.50%+51.24%+99.26% 7.23TCr
+1.25%-3.01%+40.12%+77.12% 6.02TCr
+2.12%+5.26%+32.50%+21.28% 2.77TCr
-3.06%-1.81%-13.10%+357.06% 2.57TCr
-0.75%+2.56%+0.45%-4.46% 2.47TCr
+0.40%+0.75%+22.91%-9.68% 2.07TCr
-1.70%-2.12%+146.86%+314.52% 1.51TCr
+0.36%-0.34%+50.32%+166.42% 1.44TCr
+0.21%+1.17%-8.07%+499.10% 1.42TCr
Average -1.98%-1.75%+28.11%+147.06% 2.75TCr
Weighted average by Cap. -0.77%+0.31%+36.31%+129.11%

Financials

2024 2025
Net sales - -
Net income -26.16L -18.51L -16.24L -15.34L -13.98L -18Cr -26.35L -1.84Cr -71.09L -9.06Cr -69.48L -67.98L -29Cr -47.14L -33.34L -29.26L -27.63L -25.18L -32Cr -47.48L -3.31Cr -1.28Cr -16Cr -1.25Cr -1.22Cr -52Cr
Net Debt 42.31L 29.93L 26.26L 24.8L 22.6L 29Cr 42.61L 2.97Cr 1.15Cr 15Cr 1.12Cr 1.1Cr 47Cr 28.61L 20.24L 17.76L 16.77L 15.28L 19Cr 28.81L 2.01Cr 77.73L 9.91Cr 75.98L 74.33L 32Cr
Logo Hemostemix Inc.
Hemostemix Inc. is an autologous stem cell therapy platform company. The Company has developed, patented, and is scaling and selling autologous (patient’s own) blood-based stem cell therapies that include angiogenic cell precursors (ACP-01), later neural cell precursors (NCP-01), and cardiomyocyte cell precursors (CCP-01). It holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including ACP-01, CCP-01 and NCP-01. ACP-01 is a clinically relevant and statistically significant treatment for peripheral arterial disease, chronic limb-threatening ischemia, non-ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. It has completed a Phase II clinical trial for chronic limb-threatening ischemia. It has two wholly owned subsidiaries, Kwalata Trading Limited and PreCerv Inc. PreCerv Inc. holds a global field of use license to ACP-01 & NCP-01 for the treatment of conditions of the central and peripheral nervous system.
Employees
-
Date Price Change Volume
25/26/25 CA$0.0550 -15.38% 10,000
24/26/24 CA$0.0650 0.00% 10,000
23/26/23 CA$0.0650 -7.14% 2,69,482
22/26/22 CA$0.0700 0.00% 2,577
21/26/21 CA$0.0700 0.00% 50,001